Some new concepts in antibacterial drug therapy

Indian Journal of Pharmacology

Volumn 34, Issue 6, 2002, Pages 390-399

  Sharma, K K ^a   Sangraula, H ^a   Mediratta, P K ^b  

^a B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^b UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

Antimicrobial therapy; Concentration dependent effect; Microbial resistance; Post antibiotic effect; Time dependent effect

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; EPEREZOLID; GENTAMICIN; KETOLIDE; LINEZOLID; MACROLIDE; METRONIDAZOLE; NETILMICIN; NITROIMIDAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN DERIVATIVE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANALYTICAL PARAMETERS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; MICROBIOLOGICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; OUTCOMES RESEARCH; PHARMACODYNAMICS; PNEUMONIA; POSTANTIBIOTIC EFFECT; RESPIRATORY TRACT INFECTION; REVIEW; URINARY TRACT INFECTION;

EID: 0036898850     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Leggett JE. Ambulatory use of parenteral antibacterials: Contemporary perspectives. Drugs 2000;59 Suppl 3: 1-8.
2. Cunha BA, editor. In: Antimicrobial therapy part I (Remark in preface). Med Clin North Am 1995 May; 79(3):xi-xii.
3. Nightingale CH, Quintiliani R, Nicolau DP. Intelligent dosing of antimicrobials. In: Remington JS, Swartz MN, editors. Current Clinical Topics in Infectious Diseases. Cambridge, MA: Blackwell Scientific; 1994. p. 252-65.
4. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antimicrobial dosing in mice and men. Clin Inf Dis 1998;26:1-12.
5. Nicolau DP. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 2001;29 Suppl 2:11-15.
6. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: A review. Scand J Infect Dis 1990;74 Suppl:63-7.
7. Craig WA, Vogelman B. The postantibiotic effect. Ann Intern Med 1987;106:900-2.
8. Isaksson B, Nilsson L, Maller R, Soren L. Post antibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method. J Antimicrob Chemother 1988;22:23-33.
9. Fuursted K. Post-antibiotic effect of ciprofloxacin on Pseudomonas aeruginosa. Eur J Clin Microbiol 1987;6:271-4.
10. Eliopoulos GM, Eliopoulos CT. Activity in vitro of the quinolones. In: Hooper DC, Wolfson JS, editors. Quinolone Antimicrobial Agents, 2nd ed. Washington DC: American Society of Microbiology; 1993. p. 161.
11. Debbia EA, Pesce A, Schito GC. In vitro assessment of the postantibiotic effect of lomefloxacin against gram-positive and gram-negative pathogens. Am J Med 1992;92 Suppl 4A:45-7.
12. O'Donnell JA, Gelone SP. Fluoroquinolones. Inf Dis Clin North Am 2000;14:489-513.
13. Fietta A, Morosoni M, Cascina A. Effects of continuous or pulsed exposure to rifabutin and sparfloxacin on the intracellular growth of Staphylococcus aureus and Mycobacterium tuberculosis. J Chemother 2001;13:167-75.
14. Andes D, Craig WA. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 2002;46:1665-70.
15. Fisman DN, Kaye KM. Once daily dosing of aminoglycoside antibiotics. Inf Dis Clin North Am 2000;14:475-87.
16. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infection. J Antimicrob Chemother 1991;27 Suppl C:29-40.
17. Gudmundsson S, Erlendsdothir H, Goltfredssion M, Gudmundsson A. The postantibiotic effect induced by antimicrobial combinations. Scand J Infect Dis 1990;74 Suppl:80-93.
18. Guan L, Blumenthal RM, Burnham JC. Analysis of macromolecular biosynthesis to define the quinolone-induced postantibiotic effect in E coli. Antimicrobial Agents Chemother 1992;36:2118-24.
19. Levison ME. Pharmacodynamics of antibacterial drugs. Inf Dis Clin North Am 2000;14:281-91.
20. Svensson M, Strom M, Nilsson M, Sorberg M, Nilsson LE. Pharmacodynamic effects of nitroimidazoles alone and in combination with clarithromycin on Helicobacter pylori. Antimicrob Agents Chemother 2002;46:2244-8.
21. Odenholt I, Lowdin E, Cars O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother 2001;45:23-9.
22. McDonald PJ, Wetherall BL, Prull H. Postantibiotic leukocyte enhancement: Increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 1981;3:38-44.
23. Vazifeh D, Abdelghaffar H, Labro MT. Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphyllococcus aureus in comparison with roxithromycin. Antimicrob Agents Chemother 2002;46:1364-74.
24. Kawamura-Sato K, Linuma Y, Hasegawa T, Yamashino T, Ohta M. Postantibiotic suppression effect of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. J Infect Chemother 2001;7:51-4.
25. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-99.
26. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054-60.
27. Keating MF, Bodey GP, Valdivieso M, Rodiguez M. A randomized comparative trial of three aminoglycosides - Comparison of the continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine 1979;58:159-70.
28. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R, et al. Once-daily aminoglycosides program. Experience in 2184 patients. Antimicrob Agents Chemother 1995;39:650-5.
29. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991;35:399-405.
30. Beaucaire G, Leroy O, Beuscart C, Karp P, Chidiac C, Caillaux M. Clinical and bacteriological efficacy and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother 1991;27 Suppl C:91-103.
31. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-9.
32. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81.
33. Michea-Hamzelpour M, Auckenthaler R, Regamey P, Pechere JC. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother 1987;31:1803-8.
34. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998;27:10-22.
35. Strehl E, Kees F. Pharmacological properties of parenteral cephalosporins: Rationale for ambulatory use. Drugs 2000;59 Suppl 3:9-18.
36. Craig WA. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J 1998;77 Suppl 6:7-11.
37. Schentag JJ, Smith IL, Swanson DJ, DeAngelis C, Fracasso JE, Vari A, et al. Role for dual individualization with cefmenoxime. Am J Med 1984;77 (6A):43-50.
38. Snydman DR, Cuchural GJ, McDermott L, Gill M. Correlation of various in vitro testing methods with clinical outcome in patients with bacteroides fragilis group infections treated with cefoxitin: A retrospective analysis. Antimicrob Agents Chemother 1992;36:540-4.
39. Weinstein MP, Stratton CW, Hawley HB, Ackley A. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med 1987;83:218-22.
40. Rosendaal R, Bakker-Woundenberg IA, Van Der Berg JC, Michel MF. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis 1985;152:373-8.
41. Livingston DH, Wang MT. Continuous infusion of cefazolin is superior to intermittent dosing in decreasing infection after hemorrhagic shock. Am J Surg 1993;165:203-7.
42. Lipman J, Wallis SC, Rickard CM, Fraenkel D. Low cefpirome levels during twice daily dosing in critically ill septic patients: Pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001;27:363-70.
43. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979;67:608-16.
44. VanBambeke F, Tulkens PM. Macrolides: Pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2001;18 Suppl 1: 17-23.
45. Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 1995;39:1842-7.
46. Daikos GL, Jackson GG, Lolans VT, Livermore DM. Adaptive resistance to aminoglycoside antibiotics from first exposure down-regulation. J Infect Dis 1990;162:414-20.
47. Barclay ML, Begg EJ, Chambers ST. Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrob Agents Chemother 1992;36:1951-7.
48. Romanelli G, Cravarezza P. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian intramuscular meropenem study group. J Antimicrob Chemother 1995;36 Suppl A:109-19.
49. Leder K, Turnidge JD, Grayson JL. Home-based treatment of cellulitis with twice-daily cefazolin. Med J Aust 1998;169:519-22.
50. Boucher BA, Kuhl DA, Hickeson WL. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis 1992;14:458-63.
51. Lipman J, Wallis SC, Rickard CM, Fraenkel D. Low cefpirome levels during twice daily dosing in critically ill septic patients: Pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001;27:363-70.